Loading
LEPR (Leptin receptor) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.
Receptor for hormone LEP/leptin. On ligand binding, mediates LEP central and peripheral effects through the activation of different signalling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides, also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant.
In plain words · LEPR (Leptin receptor) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.
LEPR (Leptin receptor) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Meningioma.
Receptor for hormone LEP/leptin. On ligand binding, mediates LEP central and peripheral effects through the activation of different signalling pathways such as JAK2/STAT3 and MAPK cascade/FOS.
No product in this corpus aims at LEPR yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role biomarker; HPA finds the RNA tissue enriched, which says where the protein sits but not whether the tumour differs from normal tissue. HPA LEPR: RNA tissue enriched (liver 122 nTPM); blood lineage lineage enriched (granulocytes 5 nTPM); high antibody staining in 1 normal tissue. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Brain and spinal cord tumours (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas LEPR tissue; Open Targets ENSG00000116678 associations
First described 1995. Earliest sequence paper UniProt cites for the protein: Tartaglia L.A. et al, Cell, 1995, "Identification and expression cloning of a leptin receptor, OB-R". Source.
Sources: HGNC HGNC:6554 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P48357 (protein name, function text, keywords and locations (REST API)); CIViC gene LEPR (1 evidence items, 0 assertions, 1 variants; diseases: Meningioma (GraphQL API, CC0))
Receptor for hormone LEP/leptin. On ligand binding, mediates LEP central and peripheral effects through the activation of different signalling pathways such as JAK2/STAT3 and MAPK cascade/FOS. In the hypothalamus, LEP acts as an appetite-regulating factor that induces a decrease in food intake and an increase in energy consumption by inducing anorexinogenic factors and suppressing orexigenic neuropeptides, also regulates bone mass and secretion of hypothalamo-pituitary-adrenal hormones. In the periphery, increases basal metabolism, influences reproductive function, regulates pancreatic beta-cell function and insulin secretion, is pro-angiogenic and affects innate and adaptive immunity. Control of energy homeostasis and melanocortin production (stimulation of POMC and full repression of AgRP transcription) is mediated by STAT3 signalling, whereas distinct signals regulate NPY and the control of fertility, growth and glucose homeostasis. Involved in the regulation of counter-regulatory response to hypoglycemia by inhibiting neurons of the parabrachial nucleus. Location: Cell membrane; Basolateral cell membrane; Secreted (UniProt). Locus 1p31.3 (HGNC).
RNA: tissue enriched (liver 122 nTPM), detected in all normal tissues. Blood: lineage enriched (granulocytes 5 nTPM).
RNA cancer enriched: Liver Hepatocellular Carcinoma 40 pTPM.
No cancer sample stained medium or high.
HPA LEPR tissue · HPA LEPR pathology · HPA protein class: CD markers, FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"LEPR" OR ABSTRACT:"LEPR" OR TITLE:"leptin receptor" OR ABSTRACT:"leptin receptor" OR TITLE:"Leptin receptor" OR ABSTRACT:"Leptin receptor" OR TITLE:"CD295" OR ABSTRACT:"CD295" OR TITLE:"LEP-R" OR ABSTRACT:"LEP-R" OR TITLE:"OB-R" OR ABSTRACT:"OB-R") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LEPR, not a curated reading list.
Shares Meningioma, CIViC.
Shares Meningioma, CIViC.